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Abstract
Background:  Human rhinoviruses (HRVs) are the predominant cause of common cold. In
addition, HRVs are implicated in the worsening of COPD and asthma, as well as the loss of lung
transplants. Despite significant efforts, no anti-viral agent is approved for the prevention or
treatment of HRV-infection.
Results: In this study we demonstrate that Iota-Carrageenan, a sulphated polysaccharide derived
from red seaweed, is a potent anti-rhinoviral substance in-vitro. Iota-Carrageenan reduces HRV
growth and inhibits the virus induced cythopathic effect of infected HeLa cells. In addition, Iota-
Carrageenan effectively prevents the replication of HRV1A, HRV2, HRV8, HRV14, HRV16, HRV83
and HRV84 in primary human nasal epithelial cells in culture. The data suggest that Iota-
Carrageenan acts primarily by preventing the binding or the entry of virions into the cells.
Conclusion:  Since HRV infections predominately occur in the nasal cavity and the upper
respiratory tract, a targeted treatment with a product containing Iota-Carrageenan is conceivable.
Clinical trials are needed to determine whether Iota-Carrageenan-based products are effective in
the treatment or prophylaxis of HRV infections.
Background
The family Picornaviridae comprises some notable mem-
bers, including human rhinovirus (HRV), which infects
humans more frequently than any other virus. Infections
with HRV lead to the common cold with symptoms such
as sore throat, rhinitis, nasal congestion, and cough [1].
The National Institutes of Health (NIH) estimates that
there are more than a billion cases of common colds in
the USA each year. Besides the self-limiting infection, HRV
is implicated as a cause or predisposing agent for otitis
media, sinusitis and exacerbations of asthma, as well as
other lower respiratory tract disorders [1-4].
Despite significant efforts no anti-viral agent is approved
for the prevention or treatment of HRV-infection. A
number of anti-viral compounds have been evaluated for
the management of HRV induced colds, including the
capsid binders pirodavir and Pleconaril [3,5-7]. Studies
with biologicals such as intranasal Tremacamra a soluble
intercellular adhesion molecule 1 (ICAM-1) and alpha
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interferon have shown that targeting HRV is possible espe-
cially when the drugs are applied prophylactically or the
intervention is early. [8-10].
Another approach targets the HRV proteases 2A and 3C
with small molecules. Protease 3C is an enzyme necessary
for the posttranslational cleavage of viral precursor poly-
proteins. Studies with experimental HRV infection
showed promising results for Ruprintrivir a compound
developed by (Agouron/Pfizer) [6]. Development of
Tremacamra and Ruprintrivir has not advanced to phase
III clinical trials until today.
To effectively inhibit the HRV induced inflammatory cas-
cade of the common cold the treatment needs to be initi-
ated rapidly after the first symptoms or even before. Since
the HRV infection is self limiting and not life threatening
in most cases a potential therapy has to be safe and effec-
tive with an almost unrecognizable level of side effects.
Polymers from various sources are substances that might
bear these desired safety properties. In particular sul-
phated polysaccharides including Carrageenan, a sul-
phated polysaccharide extracted from red seaweed has an
excellent safety profile and has shown anti-viral efficacy
against several viruses. The anti-HIV-1 activity of Lambda-
, Kappa- and Iota-Carrageenan and other sulphated poly-
mers has been described previously [11,12]. In a review,
Gonzalez M.E. et al. [11] report an anti-viral efficacy of
different sulphated polysaccharides including Iota-Carra-
geenan against several animal viruses. Iota-Carrageenan
showed anti-viral activity against the enveloped viruses
Herpes simplex virus type 1 and type 2, Semliki Forest
virus (SFV), vaccinia virus, African swine fever virus (ASF),
and against encephalomyocarditis (EMC) virus. Iota-Car-
rageenan had no effect on vesicular stomatitis virus (VSV),
measles virus, polio virus type 1 (member of the picorna-
viridae) and adenovirus type 5. Carlucci et al. [11,13]
demonstrated a protective effect of Lambda-Carrageenan
on genital herpes simplex virus infection in mice. Pujol et
al. [14] showed the anti-viral activity of a Carrageenan iso-
lated from Gigartina skottsbergii against intraperitoneal
murine herpes simplex virus infection.
Carrageenan has been generally recognized as safe by the
FDA. In addition, Carrageenan has been extensively used
in the food, cosmetic and pharmaceutical industry as a
thickener and gelling agent. In this report we show that
Iota-Carrageenan inhibits the replication of HRV in tissue
culture. Therefore Iota-Carrageenan might be a promising
candidate for the evaluation of efficacy against HRV in
clinical trials in humans.
Results
Carrageenan promotes cell survival after HRV2 infection
Carrageenan has been shown to bear anti-viral activity
against herpes simplex virus (HSV), cytomegalovirus
(CMV), dengue virus, papilloma virus, and human immu-
nodeficiency virus (HIV) [11,12,15,16]. To study the
effect of different Carrageenan-subtypes (Lambda-,
Kappa-, and Iota-Carrageenan) on HRV, a comparative
experiment was performed. HRV infection of cells induces
morphological changes and cell death, commonly known
as cythopathic effect (CPE). To quantify the virus induced
cell death, a proliferation assay was employed. As indica-
tor for cell survival the tetrazolium substrate conversion
into a formazan dye was measured (XTT-Test). The result-
ing optical density (OD) values reflected the metabolic
activity of cells. HeLa cells were infected with HRV2 at an
amount of input virus of 0,1 TCID50/cell. Metabolic activ-
ity was measured 48 hours post infection (p.i.), when a
CPE of more than 90% was observed by microscopy. OD
values of HRV2 infected, untreated HeLa cells were set to
0%. Survival of mock infected cells was set to 100%. Pol-
ymers Lambda-, Kappa-, and Iota-Carrageenan were
applied at a concentration of 200 μg/ml. The protection
against virus-induced cell death was 55% for Lambda-Car-
rageenan and 62% for Kappa-Carrageenan (Figure. 1A).
However, 200 μg/ml Iota-Carrageenan completely
blocked the virus induced cell death. All tested Carrageen-
ans did not show cytotoxic effects on uninfected cells up
to concentrations of 1000 μg/ml after 48 h (data not
shown).
Iota-Carrageenan reduces production of HRV particles
HeLa cells were seeded in 24-well plates (2 * 104 cells per
well) and infected with HRV2 (0,1 TCID50/cell) in the
presence of Iota-Carrageenan at a concentration of 200
μg/ml. When cell lysis was observed in the untreated con-
trol, supernatants were harvested. Viral titers were deter-
mined by TCID50 assays on HeLa cells. HRV2 replication
in untreated control cells resulted in the generation of 108
TCID50/ml after 48 h (Figure 1B). Lambda- and Kappa-
Carrageenan reduced HRV2 titers in cell supernatants by
two orders of magnitude. Iota-Carrageenan exceeded the
activity of Lambda- and Kappa-Carrageenan and pre-
vented viral titer production for at least 6 orders of magni-
tude when compared with the untreated control (Figure
1B). Since, the detection limit was 102 TCID50 in this test
an even higher effect cannot be excluded.
The anti-viral effect of Iota-Carrageenan is dependent on 
the amount of input virus
To test whether the amount of input virus has an effect on
the anti-viral properties of Iota-Carrageenan, HeLa cells
were infected with HRV2 with three different amounts of
input virus. The survival of infected HeLa cells after 72 h
was determined with an XTT assay as described above. InVirology Journal 2008, 5:107 http://www.virologyj.com/content/5/1/107
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Carrageenans promote cell viability of HRV2 infected HeLa cells and inhibit HRV2 replication in vitro Figure 1
Carrageenans promote cell viability of HRV2 infected HeLa cells and inhibit HRV2 replication in vitro. A. HeLa 
cells grown in 96-well plates were infected with HRV2 (0,1 TCID50/cell) in the presence of Carrageenans (different types are 
indicated at the x-axis) at a concentration of 200 μg/ml. Plates were incubated at 37°C until cells in the control (no polymer 
added) showed >90% damage. Cell proliferation was determined with an XTT-assay. OD values (492 nm) obtained from mock 
infected cells (compare x-axis) were set to 100%, and the viability of cells infected in the absence of polymer was set to 0% (y-
axis). The bars represent the mean of a quadruplicate experiment, the standard deviation is indicated. B. HeLa cells in 24-well 
plates were infected with HRV2 (0,1 TCID50/cell) in the presence of Carrageenans (different types are indicated at the x-axis) 
at a concentration of 200 μg/ml. Viral infectivity in the supernatants was determined by TCID50 assay on HeLa cells (y-axis). 
Values represent the mean of six parallel titrations, standard deviation is indicated.
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one arm of the experiment the infection was performed in
the presence of Iota-Carrageenan (prophyalxis experi-
ment). In the other arm of the experiment the infection
was performed in the absence of polymer (treatment
experiment). 30 minutes after infection the inocula were
removed in both groups, cells were washed and polymer
was added at concentrations ranging from 0,7 μg/ml to
400 μg/ml. A clear dependency on the amount of input
virus was observed in both tested schemes (Figure 2). At
an amount of input virus of 0,01 TCID50/cell HeLa cells
were completely protected from virus induced CPE at a
concentration as low as 4 μg/ml in both the prophylaxis
and the treatment experiment. At 0,1 TCID50/cell the pro-
tective concentration of Iota-Carrageenan increased to 10
μg/ml in the prophylaxis experiment and no protection
was observed in the treatment experiment. With input
virus of 1 TCID50/cell in the prophylaxis experiment only
the highest concentration of Iota-Carrageenan (400 μg/
ml) resulted in a partial protection and again no effect was
observed in the treatment experiment. These data suggest
that the anti-viral effect of Iota-Carrageenan is dependent
on the amount of input virus. In addition, the polymer is
more efficacious in a prophylactic setting compared to a
treatment setting.
In an analogous experiment the viral titers in supernatant
were determined. Cells were infected with HRV2 (0,1
TCID50/cell) in the presence or absence of different con-
centrations of Iota-Carrageenan. 48 h after infection
supernatants were harvested and titers were determined
with a TCID50 assay. When the infection was done in pres-
ence of Iota-Carrageenan, a dose-dependent reduction of
the viral titer was observed showing a reduction of 3
orders of magnitude at 100 μg/ml (Figure 3A). When the
polymer was added after the infection a reduction in the
viral titer of 2 orders of magnitude was observed for the
concentrations 25, 50 and 100 μg/ml. At the concentra-
tions 12,5 and 6,25 μg/ml the reduction in the viral titer
was less pronounced (Figure 3B). Similar to the CPE
assays, this experiment showed that titers of supernatants
of cells infected in the presence of Iota-Carrageenan are
reduced compared to titers of supernatants of cells
infected in the absence of Iota-Carrageenan. In order to
exclude a direct effect of the polymer to the cells we incu-
bated Hela cells with Iota-Carrageenan three hours before
infection. Cells were washed twice with PBS prior to infec-
tion with HRV. This treatment of the cells did not result in
a significant effect on cell survival and replication of HRV
(data not shown). The data imply that the anti-viral effect
of Iota-Carrageenan against HRV is due to the inhibition
of viral binding or entry into the cells.
Search for Iota-Carrageenan resistant variants
We were interested whether Iota-Carrageenan resistant
variants occur with high frequency and can be character-
ized. 6-well plates with HeLa cells (8 * 104 cells per well)
were infected in the presence of polymer with HRV2 (0,1
TCID50/cell) and 30 minutes post infection medium con-
taining a given polymer concentration was added. After
two days of incubation at 37°C a cytopathic effect was
observed in the mock treated control and supernatants
were collected. The supernatants of those wells showing
partial protection from virus induced cells death (7 μg/ml
and 20 μg/ml) were used as inoculum for the next selec-
tion round. After ten repetitive infection experiments, the
original HRV2 virus was compared with the HRV2 virus
from the last passage in a CPE inhibition experiment (for
details see material and methods; Figure 4). No significant
difference was observed in a CPE inhibition experiment
between the original HRV2 viruses that have been
obtained after ten passages. This result indicates that
escape mutants against Iota-Carrageenan do not occur fre-
quently in HeLa cells.
Iota-carageenan blocks replication of HRV2 in primary 
human nasal epithelial cells (HNep)
In order to study whether the activity against HRV is a tis-
sue culture phenomenon an experiment with human
nasal epithelial cells (HNep) was conducted. HNep cells
were grown in 24-well plates. The infection with HRV2
(0,1 TCID50/cell) was carried out in the presence or
absence of Iota-Carrageenan and 30 minutes post infec-
tion medium containing polymer in the range of 0,2 μg/
ml to 500 μg/ml was added. After 48 hours analysis of
viral titers in the supernatants of infected cells revealed
that HRV2 replicates to titers of approximately 107
TCID50/ml on HNep cells. The viral titer was below the
detection limit of 102 TCID50/ml when 55 μg/ml of Iota-
Carrageenan was already present during the infection
(Figure 5A). When the infection was done in the absence
of Iota-Carrageenan a concentration of 500 μg/ml was
needed to reduce the viral replication below the detection
limit (Figure 5B). However, in both cases a significant
reduction in the viral titer was observed when the polymer
concentration was at least 2 μg/ml. This result shows that
Iota-Carrageenan inhibits replication of HRV2 on HNep
cells.
Iota-carrageenan inhibits replication of HRV serotypes 1A, 
8, 14, 16, 83, 84 on primary human epithelial cells
Since more than 100 distinctive HRV serotypes are circu-
lating in humans it was important to reveal whether Iota-
Carrageenan is also effective against other strains of HRVs.
The work of Ledford et al. shows that the EC50 concentra-
tion against HRV of the capsid binder Pleconaril has a
strain dependent variability between 0,01 μg/ml and
>12,5 μg/ml [17]. Based on this work we selected HRV1A,
HRV16 and HRV8 for testing. These three viruses belong
to the HRV-A virus group and are in contrast to HRV2 rel-
atively insensitive to Pleconaril. From the HRV-B virusVirology Journal 2008, 5:107 http://www.virologyj.com/content/5/1/107
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Iota-Carrageenan induced inhibition of HRV2 infected cells is dependent on the amount of virus Figure 2
Iota-Carrageenan induced inhibition of HRV2 infected cells is dependent on the amount of virus. A. Preincuba-
tion of virus with polymer. HeLa cells grown in 96-well plates were infected with HRV2 in the presence of Iota-Carrageenan at 
concentrations as indicated at the x-axis. B. Treatment with polymer after infection. HeLa cells grown in 96-well plates were 
infected with HRV2. 30 minutes after infection medium containing Iota-Carrageenan at the concentrations indicated at the x-
axis was added. Plates were incubated at 37°C until cells in the control (no polymer added) showed >90% damage. Cell prolif-
eration was determined with an XTT-assay. OD values (492 nm) obtained from mock infected cells (compare x-axis) were set 
to 100%, and the viability of cells infected in the absence of polymer was set to 0% (y-axis). Black triangles indicate an amount 
of input virus of 0,01 TCID50/cell, black diamonds indicate 0,1 TCID50/cell and black squares indicate 1 TCID50/cell. A repre-
sentative experiment is shown.
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Iota-Carrageenan dose-dependently inhibits HRV2 replication in cell culture Figure 3
Iota-Carrageenan dose-dependently inhibits HRV2 replication in cell culture. (A) Preincubation of virus with poly-
mer. HeLa cells grown in 12-well plates were infected with HRV2 (0,1 TCID50/cell) in the presence of Iota-Carrageenan at the 
concentration indicated at the x-axis. 30 minutes after infection the inoculum was removed and medium containing Iota-Carra-
geenan with the concentration indicated was added. Untreated cells were used as control (mock treated). B. Treatment with 
polymer after infection. HeLa cells grown in 24-well plates were infected with HRV2 (0,1 TCID50/cell). 30 minutes after infec-
tion the inoculum was removed and medium containing Iota-Carrageenan with the concentration indicated at the x-axis was 
added. Untreated cells were used as control (mock treated). Viral titers in the supernatants of infected cells were determined 
after 48 h by TCID50 assay on HeLa cells. Values are the means from six parallel titrations, standard deviation is indicated.
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Figure 4 (see legend on next page)
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group we tested the Pleconaril sensitive strain HRV83, the
moderate sensitive strain HRV14, and HRV84, a strain
that cannot be inhibited by Pleconaril at a concentration
of 12,5 μg/ml. Primary human nasal epithelial cells were
seeded in 96-well plates (4.8 * 103 cells per well) and
infected with HRV an amount of input virus of 2 TCID50/
cell. Supernatants were harvested between 48–72 hours
after infection and the viral titers were determined by
TCID50 assays on HeLa cells. While HRV1, HRV14, HRV16
and HRV83 replicated to titers above 107  TCID50/ml,
HRV8 reached a titer of 105,1 TCID50/ml and HRV84 a titer
of 104,1 TCID50/ml (Figure 6). A Iota-Carrageenan concen-
tration of 50 μg/ml was sufficient to reduce the replication
on HNep cells of all tested viruses by more than 3 orders
of magnitude (99,9%). At a Iota-Carrageenan concentra-
tion of 5 μg/ml an inhibition of greater than 99% was
observed for HRV1, HRV14, HRV16, HRV83 and HRV84.
However, for HRV8 a reduction from 105,2 TCID50/ml to
103,8 TCID50/ml was observed at 5 g/ml Iota-Carrageenan.
No toxic effects have been observed on HNep cells at the
highest tested Iota-Carrageenan concentration of 500 μg/
ml. This result demonstrates that Iota-Carrageenan can
effectively block the replication of six distinct HRV strain
on HNEp cells.
Discussion
In this report we demonstrate that Iota-Carrageenan, a
commercial thickening agent derived from seaweed, is a
potent inhibitor of rhinovirus infectivity in vitro. Two
other related polymers Lambda- and Kappa-Carrageenan
show moderate effects and did not fully inhibit virus
induced cell death in HRV2 infected HeLa cells (Figure 1).
Protection of HeLa cells from virus induced cell death was
dependent on the amount of input virus in both cases,
when cells were infected in the presence or absence of
Iota-Carrageenan (Figure 2). When cells were treated after
infection, protection was observed only for the lowest
input amount tested (0,01 TCID50/cell; Figure 2B). There-
fore we conclude that Iota-Carrageenan most likely inhib-
its binding or entry of the virus into the cells and not a
later stage of viral replication. These findings are consist-
ent with previous studies with other viruses that have
shown that Carrageenan is active against several viruses in
vitro and in vivo [11,16,18-24].
Iota-Carrageenan has been shown to be a potent inhibitor
of papillomavirus infection with 50% inhibitory doses in
the low ng/ml range [12]. However, when tested against
rhinoviruses Iota-Carrageeenan appears to be effective
against HRV at concentrations several orders of magni-
tude higher in the low μg/ml range (Figure 3). This result
is comparable with in-vitro data of other viruses such as
HIV-1 and Herpes virus [15,25].
Repeated passage of the HIV virus in the presence of poly-
anions can lead to resistance mediated by mutations in
the envelope glycoprotein gp120, particularly in the V3
loop (K269E, Q278H, N293D), as originally shown for
dextran sulphate, and subsequently for Zintevir and nega-
tively charged albumins [26,27]. While resistant variants
emerge relatively fast with HIV-1 we were not able to
detect a difference in an in-vitro test between the original
virus stock and a HRV2 virus after 10 subsequent passages
in the presence of Iota-Carrageenan at concentrations
between 7 μg/ml and 20 μg/ml (Figure 4). Although the
potential emergence of resistant variants deserves detailed
and extensive studies we conclude that Iota-Carrageenan
resistant variants do not occur with a high frequency. This
result supports the hypothesis that Iota-Carrageenan pre-
vents HRV virions from cell attachment or cell entry in a
less specific manner when compared to the results that
were obtained by Buck and co-workers for papillomavirus
[12]. However, it cannot be excluded that resistant vari-
ants of HRV2 may occur at later passages and further stud-
ies are needed.
In situ hybridization studies have revealed that the airway
epithelial cell is the primary site of HRV infection in vivo
[28,29] and there is growing evidence that virally induced
alterations in epithelial cell biology may contribute to dis-
ease pathogenesis [30,31]. Thus we selected HNep cells as
target cells for rhinovirus infection studies. Again Iota-
Carrageenan was found to be effective against HRV2 on
Iota-Carrageenan does not induce HRV2 escape mutants after 10 passages Figure 4 (see previous page)
Iota-Carrageenan does not induce HRV2 escape mutants after 10 passages. A. HeLa cells in 6-well plates (8 * 104 
cells per well) were infected with HRV2 in the presence of Iota-Carrageenan. After infection the cells were washed and 
medium containing polymer was added at concentrations between 2 μg/ml and 100 μg/ml. Plates were incubated at 37°C until 
cells in the control (no polymer added) showed >90% damage. Living cells were fixed and stained with crystal violet staining 
solution. B. Supernatants from infected wells with Carrageenan of 20 μg/ml were used for the next infection round. For the fol-
lowing infection rounds the supernatants of wells with 7 μg/ml or 20 μg/ml were used for the subsequent infection round. 
After ten repetitive infection experiments the sensitivity of the resulting virus (white bars) to different concentrations of Iota-
Carrageenan (x-axis) was compared with that of the original virus (black bars). Cell proliferation was determined with an XTT-
assay. Survival of mock infected cells was set to 100%, and that in the absence of polymer was set to 0% (y-axis). The bars rep-
resent means of six independent experiments standard deviation is indicated.Virology Journal 2008, 5:107 http://www.virologyj.com/content/5/1/107
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Effect of Iota-carageenan on HRV2 infected human nasal epithelial cells Figure 5
Effect of Iota-carageenan on HRV2 infected human nasal epithelial cells. A. Preincubation of virus with polymer. 
HNep cells were grown in 24-well plates were infected with HRV2 (0,1 TCID50/cell) in the presence of Iota-Carrageenan at 
the concentration indicated at the x-axis. 30 minutes after infection the inoculum was removed and medium containing Iota-
Carrageenan with the concentration indicated was added. B. Treatment with polymer after infection. HNep cells were grown 
in 24-well plates were infected with HRV2 (0,1 TCID50/cell). 30 minutes after infection the inoculum was removed and medium 
containing Iota-Carrageenan with the concentration indicated at the x-axis was added. Viral titers in the supernatants of 
infected cells were determined after 48 h by TCID50 assay on HeLa cells (y-axis). Bars represent means of four parallel experi-
ments, standard deviation is indicated.
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primary human epithelial cells with similar results when
compared to the studies on HeLa cells (Figure 5). Our
study also shows that viral titers in supernatants of
infected HNep cells can vary by several orders of magni-
tude dependent on the strain (Figure 6). Replication stud-
ies with three Type A viruses HRV1A, HRV8, HRV16 and
three Type B viruses HRV14, HRV83 and HRV84 revealed
that Iota-Carrageenan is effectively inhibiting replication
of Type A and Type B rhinoviruses when the polymer is
present during infection (Figure 6). Differences between
batches of HNep cells resulted in a variation of titers of
HRV strains tested. However the anti-viral activity of Iota-
Carrageenan was comparable in all tested HNep batches
(data not shown).
Our data on primary cells are consistent with the data
from infected HeLa cells and thereby support the hypoth-
esis that Iota-Carrageenan interferes with viral replication
at a very early stage of viral infection. Most likely, the
binding of virions to the cells is hindered. It is not clear
whether Carrageenan exerts any additional effects. The
inhibitory effect of Iota-Carrageenan might be due to the
occlusion of virion surfaces involved in binding to cellular
receptors. Alternatively, obligatory conformational
Effect of Iota carageenan on the replication of HRVstrains 1A, 2, 8, 14, 16, 39, 83 and 84 on human nasal epithelial cells Figure 6
Effect of Iota carageenan on the replication of HRVstrains 1A, 2, 8, 14, 16, 39, 83 and 84 on human nasal epi-
thelial cells. HNep cells were grown in 96-well plates were infected with different HRV strains (indicated at the top of each 
panel; 0,1 TCID50/cell) in the presence of Iota-Carrageenan at the concentrations indicated at the x-axis. 30 minutes after 
infection the inoculum was removed and medium containing Iota-Carrageenan with the same concentration was added. Viral 
titers in the supernatants of infected cells were determined after 48 h by TCID50 assay on HeLa cells (y-axis). Bars represent 
means from four parallel experiments, standard deviations are indicated.
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changes in the virus may be blocked and in addition, a
post-attchment inhibitory effect may exist as described
recently for papillomaviruses [12,32].
Rhinovirus infections yearly account for huge economic
losses in terms of lost school and working days. Moreover,
recent evidence points towards rhinoviruses as a major
cause in exacerbating asthma and COPD. For a review see
Drescher et al 2007 [33]. A number of molecules and
strategies have been examined in order to combat rhino-
virus and the whole family of picornaviruses [5,12].
Despite this, no therapy has been approved for the treat-
ment of rhinovirus infections yet, and patient care
remains symptomatic.
Moreover, the efforts in therapeutic development are
hampered by the fact that more than 100 distinctive HRV
serotypes are circulating in humans. Our studies on pri-
mary HNep cells demonstrate that Iota-Carrageenan
potently inhibits the replication of the seven distinct rhi-
novirus strains HRV1, 2, 8, 14, 16, 83 and 84 (Figure 5
and Figure 6). Although we are convinced that the result
can be extrapolated for the whole family of human rhino-
viruses further experiments are needed proof the efficacy
on all strains of HRV.
Conclusion
The primary site of infection and replication of HRV in
humans is the nasal mucosa. It is tempting to speculate
that a targeted treatment of the nasal mucosa with Iota-
Carrageenan might create a hostile environment for HRV
and thereby block viral entry and replication. Carrageenan
is generally recognized as safe for use in food and topical
applications. Given the sensitivity and anti-viral effective-
ness against several strains of HRV in primary human epi-
thelial cells Iota-Carrageenan deserves consideration as a
candidate for clinical trials for the prophylaxis and treat-
ment of rhinovirus induced common cold.
Methods
Polymers
Lambda carrageen, Kappa carrageen and Iota carrageen
were purchased from FMC Biopolymers (Philadelphia,
PA). The dry polymer powders were dissolved in cell cul-
ture water (PAA, Austria) to a final concentration of 0.4%.
This stock solution was sterile filtered through a 0.45 μm
filter (Sarstedt, Germany) and stored at 4°C until use.
Viruses, cell lines and media
HRV serotypes (HRV 1A, 2, 8, 14, 16, 83, 84) were
obtained from the American Type Culture Collection
(Manassas, VA) and grown on HeLa cells. The stocks were
frozen at -80°C and virus titers were determined by
TCID50 assay. The human cervical epithelial carcinoma
cell line (HeLa) was obtained from the American Type
Culture Collection. The cells were cultivated in Dulbecco's
minimal essential medium (PAA) supplemented with
10% fetal bovine serum (PAA) and 1% antibiotic-antimy-
cotic mix (PAA) in a 37°C incubator (Sanyo, Japan; CO2:
5%, relative humidity: >95%). During virus infection and
viral experiments a medium containing 2% fetal bovine
serum and 1% antibiotic-antimycotic mix was used.
Human nasal epithelial cells were obtained from Promo-
Cell GesmbH (Heidelberg, Germany) and cultivated in
airway epithelial cell growth media (PromoCell).
Inhibition assays
For determination of anti-viral activity a CPE inhibition
assay was performed. HeLa cells were seeded in tissue cul-
ture plates 24 hours prior the experiments. At 80% conflu-
ence cells were infected with inoculums at indicated
amounts of input virus (TCID50/cell). In order to test
whether the polymers can inhibit viral replication the cells
were infected with virus in the presence or absence of pol-
ymer. For determination of the CPE plates were washed
with PBS (PAA) and stained with 1% crystal violet (Sigma,
St. Louis, MO) in 20% ethanol (?) and 3.7% formalde-
hyde (?). Cell damage was quantified with respect to
intensity of the stain retained by living cells in a plate
reader (Labsystems, Finland) at 630 nm. Alternatively, the
cell metabolism was measured with an XTT reagent kit
(Roche, Switzerland). Cell survival in the presence of
inhibitors was calculated by setting mock infected cells to
100% survival and cells infected without inhibitor to 0%
survival. Virus titers in 50% tissue culture infectious doses
(TCID50)/ml were determined according to Reed and
Muench [34].
Search for resistant variants
HeLa cells (8 * 104 cells per well) were seeded in a 6-well
plate and infected with HRV2. The cells were infected with
a polymer virus mixture at final concentrations of 200, 20,
7 and 2 μg/ml with an amount of input virus of 0,1
TCID50/cell. As control, one well was mock infected with
medium and one well was infected with mock treated
virus. After an infection time of 30 minutes the plates were
washed twice and an overlay with infection medium con-
taining polymer or control medium was added. Samples
were taken from each well when a clear cytopathic effect
was visible in the untreated control well. For the next
selection round the wells showing a clear CPE and differ-
ence to the control infection was used.
The infection cycle was repeated 10 times and the result-
ing virus sample was compared in a CPE inhibition test
with the original virus stock.Virology Journal 2008, 5:107 http://www.virologyj.com/content/5/1/107
Page 12 of 13
(page number not for citation purposes)
Competing interests
The authors AG, CM, RW, EP, are employed by Mari-
nomed. Authors HU and AP are co-founders of Mari-
nomed. AG, CM, AP, and EP are inventors on patent #
WO2008067982 held by Marinomed Biotechnologie
GmbH that relates to the content of the manuscript. Mari-
nomed Biotechnologie GmbH is financing the processing
charge of this manuscript.
Authors' contributions
AG, EP and HU participated in design and interpretation
of the experiments. RW, CM, AP and AG carried out the
viral replication studies on HeLa cells and drafted the
manuscript. CM and RW performed the experiments on
HNep cells. EP and HU contributed to experimental
designs of the study and writing of the manuscript. All
authors read and approved of the final manuscript.
Acknowledgements
We would like to thank Sekina Sadovsky-Sherif for excellent laboratory 
assistance. This work was supported in part by the Austrian Research Pro-
motion Agency (FFG) grant numbers 813886 and 818252.
References
1. Whitton JL, Cornell CT, Feuer R: Host and virus determinants of
picornavirus pathogenesis and tropism.  Nat Rev Microbiol 2005,
3:765-776.
2. Anzueto A, Niederman MS: Diagnosis and treatment of rhinovi-
rus respiratory infections.  Chest 2003, 123:1664-1672.
3. Brownlee JW, Turner RB: New developments in the epidemiol-
ogy and clinical spectrum of rhinovirus infections.  Curr Opin
Pediatr 2008, 20:67-71.
4. Pitkaranta A, Hayden FG: Rhinoviruses: important respiratory
pathogens.  Ann Med 1998, 30:529-537.
5. De Palma AM, Vliegen I, De CE, Neyts J: Selective inhibitors of
picornavirus replication.  Med Res Rev 2008.
6. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu
P, Patick AK, Smith GJ III, Zalman LS: Phase II, randomized, dou-
ble-blind, placebo-controlled studies of ruprintrivir nasal
spray 2-percent suspension for prevention and treatment of
experimentally induced rhinovirus colds in healthy volun-
teers.  Antimicrob Agents Chemother 2003, 47:3907-3916.
7. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA,
Liu S, Hudson S, Pevear DC, Collett M, McKinlay M: Efficacy and
safety of oral pleconaril for treatment of colds due to picor-
naviruses in adults: results of 2 double-blind, randomized,
placebo-controlled trials.  Clin Infect Dis 2003, 36:1523-1532.
8. Gwaltney JM Jr, Winther B, Patrie JT, Hendley JO: Combined anti-
viral-antimediator treatment for the common cold.  J Infect
Dis 2002, 186:147-154.
9. Hayden FG, Gwaltney JM Jr: Intranasal interferon-alpha 2 treat-
ment of experimental rhinoviral colds.  J Infect Dis 1984,
150:174-180.
10. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr: Prevention of
natural colds by contact prophylaxis with intranasal alpha 2-
interferon.  N Engl J Med 1986, 314:71-75.
11. Gonzalez ME, Alarcon B, Carrasco L: Polysaccharides as antiviral
agents: antiviral activity of carrageenan.  Antimicrob Agents
Chemother 1987, 31:1388-1393.
12. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT:
Carrageenan is a potent inhibitor of papillomavirus infec-
tion.  PLoS Pathog 2006, 2:e69.
13. Carlucci MJ, Scolaro LA, Noseda MD, Cerezo AS, Damonte EB: Pro-
tective effect of a natural carrageenan on genital herpes sim-
plex virus infection in mice.  Antiviral Res 2004, 64:137-141.
14. Pujol CA, Scolaro LA, Ciancia M, Matulewicz MC, Cerezo AS,
Damonte EB: Antiviral activity of a carrageenan from Gigar-
tina skottsbergii against intraperitoneal murine herpes sim-
plex virus infection.  Planta Med 2006, 72:121-125.
15. Baba M, Snoeck R, Pauwels R, De CE: Sulfated polysaccharides
are potent and selective inhibitors of various enveloped
viruses, including herpes simplex virus, cytomegalovirus,
vesicular stomatitis virus, and human immunodeficiency
virus.  Antimicrob Agents Chemother 1988, 32:1742-1745.
16. Talarico LB, Pujol CA, Zibetti RG, Faria PC, Noseda MD, Duarte ME,
Damonte EB: The antiviral activity of sulfated polysaccharides
against dengue virus is dependent on virus serotype and host
cell.  Antiviral Res 2005, 66:103-110.
17. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T,
Collett MS, Pevear DC: VP1 sequencing of all human rhinovirus
serotypes: insights into genus phylogeny and susceptibility to
antiviral capsid-binding compounds.  J Virol 2004, 78:3663-3674.
18. Carlucci MJ, Pujol CA, Ciancia M, Noseda MD, Matulewicz MC,
Damonte EB, Cerezo AS: Antiherpetic and anticoagulant prop-
erties of carrageenans from the red seaweed Gigartina sko-
ttsbergii and their cyclized derivatives: correlation between
structure and biological activity.  Int J Biol Macromol 1997,
20:97-105.
19. Carlucci MJ, Scolaro LA, Noseda MD, Cerezo AS, Damonte EB: Pro-
tective effect of a natural carrageenan on genital herpes sim-
plex virus infection in mice.  Antiviral Res 2004, 64:137-141.
20. Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, Li
J, Miller T, Robbiani M, Maguire RA, Buckheit RW Jr, Hartman TL,
Phillips DM: Carrageenan/MIV-150 (PC-815), a combination
microbicide.  Sex Transm Dis 2007, 34:9-14.
21. Girond S, Crance JM, Van Cuyck-Gandre H, Renaudet J, Deloince R:
Antiviral activity of carrageenan on hepatitis A virus replica-
tion in cell culture.  Res Virol 1991, 142:261-270.
22. Hamasuna R, Eizuru Y, Minamishima Y: Inhibition by iota-carra-
geenan of the spread of murine cytomegalovirus from the
peritoneal cavity to the blood plasma.  J Gen Virol 1994, 75(Pt
1):111-116.
23. Neurath AR, Strick N, Li YY: Anti-HIV-1 activity of anionic pol-
ymers: a comparative study of candidate microbicides.  BMC
Infect Dis 2002, 2:27.
24. Talarico LB, Damonte EB: Interference in dengue virus adsorp-
tion and uncoating by carrageenans.  Virology 2007,
363:473-485.
25. Witvrouw M, De CE: Sulfated polysaccharides extracted from
sea algae as potential antiviral drugs.  Gen Pharmacol 1997,
29:497-511.
26. Cabrera C, Witvrouw M, Gutierrez A, Clotet B, Kuipers ME, Swart
PJ, Meijer DK, Desmyter J, De CE, Este JA: Resistance of the
human immunodeficiency virus to the inhibitory action of
negatively charged albumins on virus binding to CD4.  AIDS
Res Hum Retroviruses 1999, 15:1535-1543.
27. Este JA, Schols D, De VK, Van LK, Vandamme AM, Desmyter J, De
CE: Development of resistance of human immunodeficiency
virus type 1 to dextran sulfate associated with the emer-
gence of specific mutations in the envelope gp120 glycopro-
tein.  Mol Pharmacol 1997, 52:98-104.
28. Arruda E, Boyle TR, Winther B, Pevear DC, Gwaltney JM Jr, Hayden
FG: Localization of human rhinovirus replication in the upper
respiratory tract by in situ hybridization.  J Infect Dis 1995,
171:1329-1333.
29. Bardin PG, Johnston SL, Sanderson G, Robinson BS, Pickett MA,
Fraenkel DJ, Holgate ST: Detection of rhinovirus infection of the
nasal mucosa by oligonucleotide in situ hybridization.  Am J
Respir Cell Mol Biol 1994, 10:207-213.
30. Proud D, Sanders SP, Wiehler S: Human rhinovirus infection
induces airway epithelial cell production of human beta-
defensin 2 both in vitro and in vivo.  J Immunol 2004,
172:4637-4645.
31. Spurrell JC, Wiehler S, Zaheer RS, Sanders SP, Proud D: Human air-
way epithelial cells produce IP-10 (CXCL10) in vitro and in
vivo upon rhinovirus infection.  Am J Physiol Lung Cell Mol Physiol
2005, 289:L85-L95.
32. Jakiela B, Brockman-Schneider R, Amineva S, Lee WM, Gern JE: Basal
cells of differentiated bronchial epithelium are more suscep-
tible to rhinovirus infection.  Am J Respir Cell Mol Biol 2008,
38:517-523.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2008, 5:107 http://www.virologyj.com/content/5/1/107
Page 13 of 13
(page number not for citation purposes)
33. Dreschers S, Dumitru CA, Adams C, Gulbins E: The cold case: are
rhinoviruses perfectly adapted pathogens?  Cell Mol Life Sci
2007, 64:181-191.
34. Reed LJ, Muench H: A simple method of estimating fifty per-
cent endpoints.  Am J Hyg 1938:493-497.